ArticleAntibiotics (Basel, Switzerland)2025
Occurrence and Antibiotic Resistance Risk Burden of
Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antimicrobial Resistance Profiles, Resistance Genes, and Their Association with Bacteriophage Susceptibility AmongMicroorganisms · 2026Article
- Bimetallic-doped carbon dot nanozyme for orthogonal dual-mode fluorescence-colorimetric detection of doxycycline.Mikrochimica acta · 2026Article
- Genomic and GWAS-Based Insights into Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging antimicrobial resistance in
methodThis study investigated the prevalence of antibiotic resistance and its cross-sample/territory risk burden in Vm from seafood and aquatic environment using hierarchical mixed-effects and antimicrobial resistance risk index (ARRI) modelling.
resultsAmong the Vm isolates, resistance was highest to amoxicillin (83.7%, 5.3-99.8) and streptomycin (54.6%, 95% CIs: 15.8-88.5), with generally high resistance to penicillins (58.0-98.0%), macrolides (17.2-65.8%), and colistin sulphate (80.2%). Resistance to aminoglycosides, cephalosporins, tetracyclines, and fluoroquinolones varied widely, with seafood and environmental water sources showing similar trends. Notably, resistance to nalidixic acid (47.2%, 17.3-79.4) and doxycycline (59.4%, 3.6-98.3) was prominent. Carbapenem resistance remained low, especially in seafood. Chloramphenicol resistance (32.3%, 2.7-89.0) was higher in environmental water. Trimethoprim-sulfamethoxazole resistance was relatively low (5.8%, 0.7-36.1). Ampicillin-sulbactam resistance (43.3%, 5.1-91.5) exceeded that of amoxicillin-clavulanic acid (31.8%, 0.8-96.3). The current data reveal antibiotic resistance burdens (ARBs) of Vm in seafood (ARRI ≈ 50) and waters (ARRI ≈ 46) exceeded that of human isolates (ARRI ≈ 0.01) greatly. Also, it identified Nigeria (ARRI = 7.78)/India (ARRI = 7.35) and Asia (ARRI = 56.91)/Africa (ARRI = 40.12) as hotspots of Vm ARBs.
conclusionsOverall, Vm exhibited diverse antimicrobial resistance patterns across sources with high resistance concerns and high rates against penicillins, cephalosporins, macrolides, and sometimes polymyxins. Thus, it is recommended that stricter regulations on antibiotic use in aquaculture are enforced; wastewater treatment is improved, one-health surveillance is implemented; and education of stakeholders about resistance risks, use of alternatives, and proper cooking of seafood to mitigate Vm-resistant impact is promoted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.